Mirum Pharmaceuticals Files 8-K on Financials

Ticker: MIRM · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1759425

Sentiment: neutral

Topics: financial-reporting, 8-k

Related Tickers: MIR

TL;DR

Mirum Pharma dropped an 8-K on Jan 13th covering financials. Check it for the latest.

AI Summary

Mirum Pharmaceuticals, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes information related to Regulation FD and financial statements/exhibits. Specific financial details or operational updates beyond the reporting of these categories are not detailed in the provided text.

Why It Matters

This 8-K filing provides an update on Mirum Pharmaceuticals' financial condition and results of operations, which is crucial information for investors to assess the company's performance and outlook.

Risk Assessment

Risk Level: low — The filing is a standard 8-K reporting financial information and does not indicate any immediate or significant risks.

Key Players & Entities

FAQ

What specific financial results or operational updates are detailed in this 8-K filing?

The provided text for the 8-K filing indicates it covers 'Results of Operations and Financial Condition' but does not detail specific financial figures or operational updates within the excerpt.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is January 13, 2025.

Under which section of the Securities Exchange Act is this 8-K filed?

This 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

What is Mirum Pharmaceuticals, Inc.'s principal executive office address?

Mirum Pharmaceuticals, Inc.'s principal executive offices are located at 989 East Hillsdale Boulevard, Suite 300, Foster City, California 94404.

What is the IRS Employer Identification Number for Mirum Pharmaceuticals, Inc.?

The IRS Employer Identification Number for Mirum Pharmaceuticals, Inc. is 83-1281555.

Filing Stats: 627 words · 3 min read · ~2 pages · Grade level 10.9 · Accepted 2025-01-13 08:32:19

Key Financial Figures

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 13, 2025, Mirum Pharmaceuticals, Inc. (the "Company") issued a press release announcing, among other things, the Company's preliminary unaudited net product sales for the fiscal year ended December 31, 2024, preliminary unaudited net product sales of LIVMARLI (maralixibat) oral solution and CHOLBAM and CHENODAL, and preliminary unaudited cash, cash equivalents and investments. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 13, 2025, in connection with its participation in the J.P. Morgan Healthcare Conference, the Company posted a corporate slide presentation in the "Investors" portion of its website at www.mirumpharma.com. A copy of the presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.2. The information in this Current Report on Form 8-K, including Exhibit 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated January 13, 2025 99.2 Investor Presentation dated January 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Mirum Pharmaceuticals, Inc. Date: January 13, 2025 By: /s/ Christopher Peetz Christopher Peetz Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing